Filter articles using the following links

EVER 2019, Nice (FR)

3rd Annual Gene Therapy for Rare Disorders Europe, London (UK)

GenSight Biologics reports evidence of GS010 DNA transfer to contralateral eye of primates unilaterally injected with GS010 Gene Therapy

GenSight Biologics Appoints Magali Taiel as Chief Medical Officer

GenSight Biologics to present new GS010 data at the 2019 Annual Meeting of the American Academy of Ophthalmology

GenSight Biologics integrates the Enternext® PEA-PME 150 index by Euronext

Future is now: Leaders in Ocular Gene Therapy Meeting, San Francisco (CA)

GenSight Biologics reports sustained efficacy and safety at 96 weeks in RESCUE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

Ophthalmology Innovation Summit @ AAO, San Francisco (CA)

American Academy of Ophthalmology, San Francisco (CA)